Analysis of redox status and HDL subclasses in patients with lymphoma and the associations with FDG-PET/CT findings

被引:1
作者
Mirjanic-Azaric, Bosa [1 ,2 ]
Stankovic, Sinisa [3 ,4 ]
Nezic, Lana [5 ]
Radic Savic, Zana [1 ]
Malcic- Zanic, Dragana [6 ]
Skrbic, Ranko [5 ,7 ]
Kotur-Stevuljevic, Jelena [8 ]
Bogavac-Stanojevic, Natasa [8 ]
机构
[1] Univ Banja Luka, Fac Med, Dept Biochem, Banja Luka, Bosnia & Herceg
[2] Univ Clin Ctr Republ Srpska, Inst Lab Diag, Banja Luka 78000, Bosnia & Herceg
[3] Univ Clin Ctr Republ Srpska, Internal Med, Banja Luka, Bosnia & Herceg
[4] Univ Banja Luka, Fac Med, Banja Luka, Bosnia & Herceg
[5] Univ Banja Luka, Fac Med, Dept Pharmacol Toxicol & Clin Pharmacol, Banja Luka, Bosnia & Herceg
[6] Univ Banja Luka, Fac Med, Dept Pediat, Banja Luka, Bosnia & Herceg
[7] Acad Sci & Arts Republ Srpska, Banja Luka, Bosnia & Herceg
[8] Univ Belgrade, Fac Pharm, Dept Med Biochem, Belgrade, Serbia
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
redox status; HDL subclasses; SUVmax; Hodgkin lymphoma; non-Hodgkin lymphoma; OXIDATION PROTEIN PRODUCTS; HEALTH-ORGANIZATION CLASSIFICATION; TOTAL OXIDANT/ANTIOXIDANT STATUS; HIGH-DENSITY-LIPOPROTEIN; HODGKIN-LYMPHOMA; STRESS; LDL; CHOLESTEROL; PON1; CHEMOTHERAPY;
D O I
10.3389/fonc.2023.1221414
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Newer research points to alterations in the plasma redox status and the HDL subclass distributions in cancer. We aimed to assess the redox status and the HDL subclass distributions, lipids, and inflammatory markers in lymphoma patients in order to determine whether they were correlated with changes in FDG-PET/CT scans. At the beginning of this study, redox status, HDL subclasses, lipids, and inflammation biomarkers were determined in 58 patients with lymphoma (Hodgkin lymphoma, n=11 and non-Hodgkin lymphoma, n=47), and these same measurements were reassessed during their ensuing treatment (in 25 patients). Initially, the total oxidation status (TOS), the prooxidant-antioxidant balance (PAB), the OS index (OSI), the total protein sulfhydryl groups (SH-groups), and the advanced oxidation protein products (AOPP) were significantly higher in lymphoma patients as compared to healthy subjects, but the total antioxidant status (TAS) was significantly reduced. The PAB had a strong correlation with the CRP and interleukin-6 (rho=0.726, p<0.001; rho=0.386, p=0.003). The correlations between these parameters and the maximum standardized uptake values (SUVmax) were: PAB, rho=0.335 and p=0.010; SH-groups, rho=0.265 and p=0.044; CRP, rho=0.391 and p=0.002; HDL3b, rho=0.283 and p=0.031; HDL2b, rho= -0.294 and p=0.025; and HDL size, rho= -0.295 and p=0.024. The reductions in SUVmax between two follow-up points were associated with increases in the OSI, TOS, and SH-groups, as well as a reduction in the PAB and TAS. In conclusion, the redox parameters in patients with lymphoma were consistent with FDG-PET/CT findings. Targeting the redox status parameters and the HDL subclasses could be potential strategies in the molecular fight against lymphoma.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] The effect of reduced scan time on response assessment FDG-PET/CT imaging using Deauville score in patients with lymphoma
    Hornnes, Charlotte
    Loft, Annika
    Hojgaard, Liselotte
    Andersen, Flemming Littrup
    EUROPEAN JOURNAL OF HYBRID IMAGING, 2021, 5 (01):
  • [22] The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma
    Bhojwani, Deepa
    McCarville, Mary B.
    Choi, John K.
    Sawyer, Jennifer
    Metzger, Monika L.
    Inaba, Hiroto
    Davidoff, Andrew M.
    Gold, Robert
    Shulkin, Barry L.
    Sandlund, John T.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (06) : 845 - 853
  • [23] Bone marrow FDG-PET/CT in Hodgkin lymphoma revisited: do imaging and pathology match?
    Adams, Hugo J. A.
    Kwee, Thomas C.
    Fijnheer, Rob
    Dubois, Steven V.
    Nievelstein, Rutger A. J.
    de Klerk, John M. H.
    ANNALS OF NUCLEAR MEDICINE, 2015, 29 (02) : 132 - 137
  • [24] Interim FDG-PET/CT in Hodgkin lymphoma: what are we actually looking at?
    Adams, Hugo J. A.
    Kwee, Thomas C.
    ACTA ONCOLOGICA, 2018, 57 (08) : 1128 - 1130
  • [25] Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin's Lymphoma
    Al-Ibraheem, Akram
    Anwer, Farah
    Juweid, Malik E.
    Shagera, Qaid Ahmed
    Khalaf, Aysar N.
    Obeidat, Shahed
    Mansour, Areen
    Ma'koseh, Mohammad
    Halahleh, Khalid
    Jaradat, Imad
    Almasri, Nidal
    Mansour, Asem
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [26] Differentiating Hodgkin Lymphoma and Sarcoid Reaction in Subsequent FDG-PET/CT: A Case Report and Literature Review
    Rabei, Obayda
    Al-Rasheed, Ula
    Alrammahi, Mohammed
    Al-Ibraheem, Akram
    WORLD JOURNAL OF NUCLEAR MEDICINE, 2023, 22 (04) : 306 - 309
  • [27] Radiation-Induced Giant Cell Granuloma Mimicking Relapsed Hodgkin Lymphoma at FDG-PET/CT
    Adams H.J.A.
    de Klerk J.M.H.
    Regelink J.C.
    Heggelman B.G.F.
    Dubois S.V.
    Kwee T.C.
    Nuclear Medicine and Molecular Imaging, 2017, 51 (4) : 371 - 373
  • [28] Pathogenesis and FDG-PET/CT findings of Epstein-Barr virus-related lymphoid neoplasms
    Toriihara, Akira
    Nakajima, Reiko
    Arai, Ayako
    Nakadate, Masashi
    Abe, Koichiro
    Kubota, Kazunori
    Tateishi, Ukihide
    ANNALS OF NUCLEAR MEDICINE, 2017, 31 (06) : 425 - 436
  • [29] The Incidence of Pulmonary Embolism and Associated FDG-PET Findings in IV Contrast-Enhanced PET/CT
    Flavell, Robert R.
    Behr, Spencer C.
    Brunsing, Ryan L.
    Naeger, David M.
    Pampaloni, Miguel Hernandez
    ACADEMIC RADIOLOGY, 2014, 21 (06) : 718 - 725
  • [30] Non-Hodgkin lymphoma localization in the pituitary gland - Diagnosis by FDG-PET/CT
    Soussan, Michael
    Wartski, Myriam
    Ezra, Jonathan
    Glaisner, Sylvie
    Pecking, Alain-Paul
    Alberini, Jean-Louis
    CLINICAL NUCLEAR MEDICINE, 2008, 33 (02) : 111 - 112